MicroTransponder
Founded Year
2007Stage
Series E | AliveTotal Raised
$125.05MLast Raised
$73M | 9 mos agoAbout MicroTransponder
MicroTransponder is a global medical device company committed to developing research-based neuroscience solutions. The company focuses on restoring independence and dignity for people suffering from neurological conditions that impair sensory and motor function. MicroTransponder's FDA-approved Vivistim® Paired VNS™ System is a clinically-proven medical technology that generates more improvement in upper limb function than rehabilitation alone for stroke survivors after 6 weeks of in-clinic therapy. MicroTransponder was founded in 2007 and is based in Austin, Texas.
Missing: MicroTransponder's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: MicroTransponder's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing MicroTransponder
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
MicroTransponder is included in 3 Expert Collections, including Medical Devices.
Medical Devices
9,125 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Digital Health
12,956 items
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Health IT
7,901 items
MicroTransponder Patents
MicroTransponder has filed 31 patents.
The 3 most popular patent topics include:
- Anxiety disorders
- Electrophysiology
- Implants (medicine)
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
2/25/2019 | 1/17/2023 | Psychotherapy, Cognitive behavioral therapy, Behaviorism, Phobias, Vagus nerve | Grant |
Application Date | 2/25/2019 |
|---|---|
Grant Date | 1/17/2023 |
Title | |
Related Topics | Psychotherapy, Cognitive behavioral therapy, Behaviorism, Phobias, Vagus nerve |
Status | Grant |
Latest MicroTransponder News
Feb 3, 2023
MicroTransponder’s Vivistim Paired VNS System was granted transitional pass-through status by the Centers for Medicare and Medicaid Services. The Centers for Medicare and Medicaid Services (CMS) awarded the MicroTransponder Vivistim Paired VNS System transitional pass-through status, expanding access to Medicare beneficiaries who are ischemic stroke survivors interested in using the breakthrough technology to help improve their hand and arm mobility. The Vivistim Paired VNS System is an FDA Breakthrough Device that was granted pre-market authorization (PMA) approval. The Vivistim System is used with rehabilitation therapy to help ischemic stroke survivors with chronic arm and hand deficits improve their upper limb function. Enhancing the effectiveness of rehabilitation therapy, Paired VNS Therapy is clinically proven to generate two to three times more hand and arm function than rehabilitation alone. To benefit from the system, ischemic stroke survivors will have the small Vivistim device implanted in their upper left chest area during an outpatient procedure. Once cleared for rehabilitation, they engage in physical or occupational therapy where a therapist uses a wireless transmitter to signal the Vivistim device to deliver a gentle pulse to the vagus nerve while the stroke survivor performs a specific task, such as putting on a hat, brushing hair or cutting food. The simultaneous pairing of the rehabilitation exercise in high repetitions with vagus nerve stimulation helps increase neuroplasticity and strengthens neural connections to improve upper limb function. “Hospitals treating stroke survivors with the Vivistim System are now eligible for additional reimbursement through Medicare’s outpatient prospective payment system,” said Richard Foust, MicroTransponder’s chief executive officer. “As a result, there’s now another pathway for stroke survivors to benefit from Paired VNS Therapy at the recommendation of their healthcare providers.” Neurological and rehabilitation specialists at premier comprehensive stroke centers and rehabilitation centers report that the Vivistim Paired VNS System helps ischemic stroke survivors improve their quality of life by increasing their ability to perform activities of daily living. “The life-changing clinical outcomes of Vivistim Paired VNS Therapy that are already being reported across the country affirm CMS’ determination that the Vivistim System is novel and represents a substantial clinical improvement over existing technologies,” said Doug Ellison, MicroTransponder’s chief revenue officer. “As we advance Vivistim commercialization, CMS’ pass-through status enables providers to realize the clinical, operational, and financial benefits of adopting Vivistim as their standard of care for chronic ischemic stroke rehabilitation.” Photo courtesy of MicroTransponder
MicroTransponder Frequently Asked Questions (FAQ)
When was MicroTransponder founded?
MicroTransponder was founded in 2007.
Where is MicroTransponder's headquarters?
MicroTransponder's headquarters is located at 2802 Flintrock Trace, Austin.
What is MicroTransponder's latest funding round?
MicroTransponder's latest funding round is Series E.
How much did MicroTransponder raise?
MicroTransponder raised a total of $125.05M.
Who are the investors of MicroTransponder?
Investors of MicroTransponder include Green Park & Golf Ventures, U.S. Venture Partners, Osage University Partners, The Vertical Group, Action Potential Venture Capital and 6 more.
Who are MicroTransponder's competitors?
Competitors of MicroTransponder include Endologix, Flowonix Medical, NxThera, Zyga Technology, Cabochon Aesthetics, Spinal Restoration, OtoKinetics, Interventional Spine, Concentric Medical, Symbios Medical Products and 14 more.
Compare MicroTransponder to Competitors
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.
Axial Biotech, founded in 2002 by a group of spine surgeons and geneticists, is focused on the use of genetics and the development of minimally invasive fusionless devices to advance the diagnosis and treatment of diseases and deformities of the human spine. Axial is a company to pursue DNA-based pre-symptomatic and prognostic tests for common spinal conditions which will augment current clinical and surgical practices. In its initial genetic product development initiative, Axial has made progress towards the discovery of a location in the human genome that is associated with adolescent idiopathic scoliosis. In addition, Axial's founders have developed five motion preserving, fusionless surgical devices (including such device currently being implanted in humans) that have the promise of expanding the current treatable scoliosis patient population by a factor of ten. Axial intends to use its genetic intellectual property in the development of bio-mechanical devices, and to apply its gene discovery/product development methodology to other spinal diseases. Axial (www.axialbiotech.com) is located in Salt Lake City, Utah.
Spinal Restoration restores patients' lives by delivering new therapies that address unmet needs in spine health management. These therapies are minimally invasive, early interventions with clinically proven results. The company is working with a diverse, highly regarded group of clinical and scientific advisors to develop and gain regulatory approval of the Biostat System, a proprietary resorbable biologic and delivery system for the treatment of chronic disc pain, based on solid scientific and clinical evidence.
Interventional Spine, fka Triage Medical, is a medical device company focused on the design, development, and marketing of patented percutaneous systems to treat lower back pain. Interventional Spine's expandable cage technology provides optimal tactile feedback for the surgeon, and features a continuously adjustable design that allows the surgeon to customize the device height to the patient's anatomy. The implants are designed to maximize bone graft contact and containment, which helps promote bone growth and fusion. The company was founded in 2000 and is based in Irvine, California.
Flowonix designs, develops, and deploys targeted drug delivery platforms whose sole purpose is to provide physicians an optimal solution for the treatment of their patients' numerous neurological disorders.
DuoCure offers intraluminal minimally invasive implantable device for treatment of obesity.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.